Adakveo (crizanlizumab) is the first and only FDA-approved intravenous (IV) infusion used to lower the number of pain crises in people with sickle cell disease. After your first month of treatment, you only need to get the infusions once a month. But you have to receive it at your provider's office. This medication is brand name only and can be expensive.
Lessen the number of vaso-occlusive crises (pain crises) in people aged 16 years and older with sickle cell disease (SCD)
Adakveo (crizanlizumab) is a monoclonal antibody that binds to P-selectin, which is a sticky protein that normally plays a role in blocking blood flow.
In people with sickle cell anemia, P-selectin gets activated when blood vessels are damaged by the sickled red blood cells. This causes your red blood cells, white blood cells, and platelets to stick together and block blood flow, which results in pain crises.
By binding to P-selectin, Adakveo (crizanlizumab) stops your blood cells from sticking together. This means your blood can flow better, which lowers the amount of pain crises.
Source: DailyMed
Side effects that you should report to your care team as soon as possible:
Side effects that usually do not require medical attention (report these to your care team if they continue or are bothersome):
Given once a month (after your first 2 doses at Week 0 and Week 2)
Infusion only takes about half an hour
Can lessen the number of pain crises by nearly half (after 1 year)
Not approved for children younger than 16 years old
Can cause infusion-related reactions
Must get infusion regularly; not meant to treat pain crises on an as-needed basis
It's possible to experience a infusion-related reaction up to 24 hours after your infusion of Adakveo (crizanlizumab). Monitor yourself for symptoms even after you go home. Get medical help right away if you experience symptoms such as fever, difficulty breathing, and hives.
Use a calendar to help stay on track for your Adakveo (crizanlizumab) infusion appointments. Missing an appointment or rescheduling often can affect how well the medication works for you. If you miss your infusion appointment, contact your provider as soon as you can to reschedule.
Adakveo (crizanlizumab) is meant to be a long-term treatment. Keep appointments with your healthcare provider while you're receiving treatments so they can monitor your progress and pain crises. Don't stop receiving these infusions unless your provider tells you to stop.
Tell your provider and pharmacist about all of the medications you take, including prescription and over-the-counter medications, vitamins, and herbal supplements, to make sure they're safe to take with Adakveo (crizanlizumab).
While receiving Adakveo (crizanlizumab), try to also follow these general tips for staying healthy with sickle cell disease.
Adakveo (crizanlizumab) can cause some serious health issues. This risk may be even higher for certain groups. If this worries you, talk to your doctor or pharmacist about other options.
Risk factors: First or second Adakveo (crizanlizumab) infusion
Adakveo (crizanlizumab) can cause you to have a reaction either during the infusion or even up to 24 hours after you've received the infusion. This is most likely to happen after your first or second infusion. In many cases, your provider can slow down the rate of your infusion, or give you medication to manage your infusion-related symptoms. If the reaction is severe enough (e.g., hives, shortness of breath), your provider might stop the infusion altogether. Let your provider know right away if you develop pain in your body, headache, fever, chills or shivering, feeling sick to your stomach, diarrhea, difficulty breathing, or dizziness.
Make sure to tell all of your healthcare providers that you're receiving Adakveo (crizanlizumab) before getting certain blood tests drawn. Adakveo (crizanlizumab) can interfere with the results of a laboratory test commonly used to measure your platelet counts.
Dosage | Quantity | Price as low as | Price per unit |
---|---|---|---|
10ml of 10mg/ml | 5 vials | $12080.47 | $2416.09 |
Adakveo (crizanlizumab) is only available as an intravenous (IV) infusion that's administered by a healthcare provider.
Your dose of Adakveo (crizanlizumab) depends on your weight. In general, the typical dose is 5 mg/kg, given as an IV infusion over a period of 30 minutes, at Week 0, Week 2, and then every 4 weeks thereafter.
Lessen the number of vaso-occlusive crises (pain crises) in people aged 16 years and older with sickle cell disease (SCD)
To lower the number of pain crises and need for blood transfusions in people with sickle cell anemia
Reducing complications of sickle cell disease in people 5 years and older
By signing up, I agree to GoodRx's Terms and Privacy Policy, and to receive marketing messages from GoodRx.
Research prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.